Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 17, 2008

View Archived Issues

Experiments reveal anticancer mechanisms of CXCR4 antagonists

Evidence of activity seen with CP-751871 in phase I sarcoma study

New agents for dermatitis disclosed in recent Kyowa Hakko Kirin patent

New therapeutic agents for eye disorders imparted in recent Santen patent

Recent patents describe novel treatments for neurological disorders

BIBW-2992 evaluated in combination with paclitaxel for solid tumors

Sirion presents pivotal uveitis data for Durezol

Cleveland BioLabs doses first healthy volunteer in Protectan CBLB-502 study

Development of BI-2536 in pancreatic cancer patients not warranted as a result of interim analysis

Grifols obtains marketing license for Flebogamma DIF in Australia

R&D highlights from the UBS Global Life Sciences Conference in New York: Advanced BioHealing

Obesity candidate GRC-9332 described by Glenmark Pharmaceuticals

FDA to review Theravance's NDA for telavancin in treatment of cSSSI in November 2008

Seattle Genetics initiates phase I clinical trial of PSMA-targeted ADC in prostate cancer

MHRA grants approval to Insmed for phase I clinical study of INS-20

Wyeth not to pursue European MAA for desvenlafaxine in MDD

NeoPharm signs CRADA with NINDS for research on IL-13 in untreatable brain diseases

Invitrogen and Applied Biosystems amend merger agreement to eliminate tax opinion condition

Genzyme initiates enrollment in clinical trial of low-dose Fabrazyme in Fabry's disease

Alcon signs licensing agreement with GSK for cilomilast and expands alliance with Origenis

Advaxis provides complete response to FDA regarding IND for phase II trial of Lovaxin C

Bayer Schering Pharma completes decentralized approval procedure in EU for Qlaira

FDA grants orphan drug status to Reata's RTA-402 for pancreatic cancer

GlaxoSmithKline obtains approval in Japan for Lamictal in epilepsy

Lorus receives milestone payment from Zor and extends license agreement for Virulizin

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
Novel caspase-2 inhibitor shows in vivo neuroprotective effects
BioWorld Science
Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...